Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y7CI
|
|||
| Former ID |
DNC001348
|
|||
| Drug Name |
SNC-80
|
|||
| Synonyms |
Snc 80; Snc-80; 156727-74-1; CHEMBL13470; SNC80; NSC707484; 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamide; NCGC00024777-02; DSSTox_RID_81039; DSSTox_CID_25662; DSSTox_GSID_45662; 4-((2,5-Dimethyl-4-(2-propenyl)-1-piperazinyl)(3-methoxyphenyl)methyl)-N,N-diethylbenzamide (2S-(1(S*),2alpha,5beta))-; Benzamide, 4-((2,5-dimethyl-4-(2-propenyl)-1-piperazinyl)(3-methoxyphenyl)methyl)-N,N-diethyl-, (2S-(1(S*),2alpha,5bet))-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H39N3O2
|
|||
| Canonical SMILES |
CCN(CC)C(=O)C1=CC=C(C=C1)C(C2=CC(=CC=C2)OC)N3CC(N(CC3C)CC=C)C
|
|||
| InChI |
1S/C28H39N3O2/c1-7-17-30-19-22(5)31(20-21(30)4)27(25-11-10-12-26(18-25)33-6)23-13-15-24(16-14-23)28(32)29(8-2)9-3/h7,10-16,18,21-22,27H,1,8-9,17,19-20H2,2-6H3/t21-,22+,27-/m1/s1
|
|||
| InChIKey |
KQWVAUSXZDRQPZ-UMTXDNHDSA-N
|
|||
| CAS Number |
CAS 156727-74-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
529434, 10240915, 11113691, 11442535, 14833255, 26751883, 29304095, 49876690, 75498274, 85788618, 91746426, 103175041, 103946292, 104419665, 124886943, 126671676, 128421771, 134222928, 135078669, 135651062, 135697536, 137166400, 142093555, 144204476, 152344284, 162022466, 164233713, 164765031, 170466880, 170485796, 223660400, 227013170, 241181876, 241377470, 252160122, 252216323
|
|||
| ChEBI ID |
CHEBI:109556
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor delta (OPRD1) | Target Info | Agonist | [2], [3] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Sphingolipid signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Opioid proenkephalin pathway | ||||
| Opioid proopiomelanocortin pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1611). | |||
| REF 2 | Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology. 2002 Jun;26(6):744-55. | |||
| REF 3 | Antiparkinson potential of delta-opioid receptor agonists. Eur J Pharmacol. 2000 May 19;396(2-3):101-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.